|
|
Case Studies of Clinical Outsourcing Approaches at Leading Biopharmaceutical CompaniesProduct Type: Market Research ReportPublished by: IDC Published: April 2005 Product Code: R104-19060 Description
This Life Science Insights study provides analysis of case studies that document the successful approaches of companies that leverage contract research organizations (CROs) to aid in drug development initiatives. The goal of this study is to identify specific contract research buying trends and patterns while also providing an overview of best practices and lessons learned. Life Science Insights expects trial sponsors will continue to beef up their research outsourcing functions and will develop replicable tools to ensure the success of every step of the outsourcing project. We also believe that sponsors will increase their interest in establishing risk sharing in CRO contracts, despite the fact that many CROs do not engage in risk sharing at this time. "Sponsors and CROs must set attainable and measurable goals in order to maximize value and minimize risk. We believe clinical trials management solutions and other technologies will increasingly be leveraged to measure and monitor these goals," said Ellen Julian, research director responsible for pharmaceutical outsourcing coverage at Life Science Insights. Table of Contents
Table of ContentsLife Science insights opinion In This Study Methodology Situation Overview Outsourcing Drivers Selection Criteria Table: Sample Contract Research Organization Score Sheet Lessons Learned Future Plans Case Studies Large Pharmaceutical Company (>$10 Billion in Revenue, Publicly Traded) Defining the Need for Outsourcing to CROs The Selection Process Lessons Learned Future Plans Midsize Pharmaceutical Company (>$3 Billion in Revenue, Privately Held) Defining the Need for Outsourcing to CROs The Selection Process Lessons Learned Future Plans Small Pharmaceutical Company (<$100 Million in Revenue, Publicly Traded) Defining the Need for Outsourcing to CROs The Selection Process Lessons Learned Future Plans Large Biotechnology Company (>$3 Billion in Revenue, Publicly Traded) Defining the Need for Outsourcing to CROs The Selection Process Lessons Learned Future Plans Large Biotechnology Company (>$2 Billion in Revenue, Publicly Traded) Defining the Need for Outsourcing to CROs The Selection Process Lessons Learned Future Plans Small Biotechnology Company (<$40 Million in Revenue, Privately Held) Defining the Need for Outsourcing to CROs The Selection Process Lessons Learned Future Plans Small Medical Device Company (<$30 Million in Revenue, Privately Held) Defining the Need for Outsourcing to CROs The Selection Process Lessons Learned Future Plans Future Outlook Essential Guidance Actions to Consider Learn More Related Research Synopsis |
|
||||||||
MindBranch has been the leading provider of industry and investment research from more than 550 independent research firms since 1992. With over 90,000 market research reports, MindBranch is your trusted source of competitive business intelligence. |